Clorox Q3 FY26 Earnings Reveal Mixed Performance, Margin Pressure and Integration Costs Ahead of FY26 Outlook

Clorox reported net sales of $1.67 billion for the quarter ended March 31, 2026, unchanged from the same period a year earlier. Organic sales slipped 1%, reflecting a combination of weaker price mix and a 1‑point volume decline after a prior‑year inventory build‑up tied to an ERP transition. Gross margin contracted 140 basis points to 43.2% as manufacturing and logistics expenses rose, partially offset by cost‑saving initiatives. On a GAAP basis, diluted earnings per share (EPS) rose 3% to $1.54, while the non‑GAAP adjusted EPS climbed 13% to $1.64, driven by lower advertising spend, reduced selling and administrative costs, and the exclusion of a cyber‑attack insurance recovery that boosted the prior‑year figure.

The quarter’s operating performance was uneven across Clorox’s four reportable segments. The Health & Wellness unit, which houses the core cleaning brands, posted flat sales and a 7% dip in adjusted EBIT as higher production costs ate into profitability. By contrast, the Household segment (bags, wraps, cat litter, grilling) delivered a 3% sales increase and a 21% jump in adjusted EBIT, reflecting strong demand for disposable and outdoor‑cooking products. Lifestyle, which includes Burt’s Bees and water‑filtration offerings, saw a 9% sales decline and flat earnings, while International sales rose 8% on the back of favorable foreign‑exchange effects and a 2% organic volume gain.

A key driver of the updated FY26 outlook is the inventory draw‑down that will occur as retailers consume the two‑weeks of extra stock built at the end of FY25. Clorox estimates the draw‑down will shave roughly 7.5 percentage points from year‑over‑year sales growth and cut diluted EPS by about $0.90, translating into a 30% decline in GAAP EPS versus FY25. The company also incorporated the financial impact of its April 1 acquisition of GOJO Industries, the maker of Purell hand‑sanitizer. GOJO is expected to add roughly 3 points of sales growth but will dilute adjusted EPS by 2–4 cents per share due to one‑quarter profit contribution and the interest expense on the debt used to fund the deal. The acquisition is EBITDA‑margin neutral but brings a different cost structure that adds roughly 60 basis points of gross‑margin headwind.

Margin pressure is further amplified by higher energy costs linked to the Middle‑East conflict and by a $0.60‑$0.70 per‑share charge for the $580 million digital‑transformation program that concluded in Q3. The program, which replaced Clorox’s legacy ERP with a cloud‑based platform, generated incremental operating costs of about $10 million in the quarter but is expected to deliver long‑term efficiencies in supply‑chain and e‑commerce execution. Those costs are excluded from adjusted EPS, yet they underscore the company’s near‑term cash‑flow drag. Indeed, operating cash flow fell to $282 million, a 59% decline from the prior year, largely because of a termination payment tied to the Glad joint‑venture.

From an investor perspective, the stock is trading at $96.44, roughly 30% below its 52‑week high of $139.48 and just above its 52‑week low of $93.39. The relative strength index (RSI) of 28 signals that the shares are oversold, while the price is still below both the 50‑day (≈$105) and 200‑day (≈$111) moving averages, suggesting continued bearish momentum. Consensus price targets average $117.33, implying about a 22% upside potential if the company can navigate the short‑term headwinds and deliver on its FY26 guidance. However, analysts such as Jefferies have recently trimmed their price targets and flagged a tougher second half, citing the inventory draw‑down and margin compression as key risks.

Overall, Clorox’s Q3 results highlight a company in transition: solid brand equity and growth in select categories are being offset by supply‑chain cost inflation, inventory timing issues, and the integration burden of GOJO. Investors will be watching the upcoming Q4 earnings for signs that the inventory pull‑through materializes, that the GOJO acquisition begins to contribute beyond the first quarter, and that the digital transformation starts delivering the promised cost efficiencies. Until those metrics improve, the stock may remain volatile, but the long‑term upside remains anchored in the company’s strong cash position, resilient consumer staples franchise, and the expanding hand‑sanitation market.